Clinical trial NCT01275521 - References

Prostatic Hyperplasia — A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy

Citation(s)

•   Barrack ER, Bujnovszky P, Walsh PC
  Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. Cancer Res. 1983 Mar;43(3):1107-16.
•   Boyle P, Gould AL, Roehrborn CG
  Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996 Sep;48(3):398-405.
•   Chute CG, Stephenson WP, Guess HA, Lieber M
  Benign prostatic hyperplasia: a population-based study. Eur Urol. 1991;20 Suppl 1:11-7.
•   Colombel M, Vacherot F, Diez SG, Fontaine E, Buttyan R, Chopin D
  Zonal variation of apoptosis and proliferation in the normal prostate and in benign prostatic hyperplasia. Br J Urol. 1998 Sep;82(3):380-5.
•   Costa P, Ben Naoum K, Boukaram M, Wagner L, Louis JF
  [Benign prostatic hyperplasia (BPH): prevalence in general practice and practical approach of French general practitioners. Results of a study based on 17,953 patients]. Prog Urol. 2004 Feb;14(1):33-9. French.
•   Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, Meehan AG, Bautista OM, Noble WR, Kusek JW, Nyberg LM, Roehrborn CG; MTOPS RESEARCH Group
  Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol. 2006 Apr;175(4):1422-6; discussion 1426-7.
•   Desgrandchamps F
  [Combination therapy in benign prostatic hyperplasia (BPH)]. Ann Urol (Paris). 2004 Dec;38 Suppl 2:S24-8. Review. French.
•   Frick J
  [Pathophysiology of benign prostatic hyperplasia]. Wien Med Wochenschr. 1996;146(8):158-60. Review. German.
•   Hieble JP, Boyce AJ, Caine M
  Comparison of the alpha-adrenoceptor characteristics in human and canine prostate. Fed Proc. 1986 Oct;45(11):2609-14.
•   Hieble JP, Ruffolo RR Jr
  The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview. Pharmacol Res. 1996 Mar;33(3):145-60. Review.
•   Isaacs JT, Coffey DS
  Etiology and disease process of benign prostatic hyperplasia. Prostate Suppl. 1989;2:33-50. Review.
•   Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM
  Treatment for benign prostatic hyperplasia among community dwelling men: the Olmsted County study of urinary symptoms and health status. J Urol. 1999 Oct;162(4):1301-6.
•   Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ
  EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004 Nov;46(5):547-54.
•   Marcelli M, Shao TC, Li X, Yin H, Marani M, Denner L, Teng B, Cunningham GR
  Induction of apoptosis in BPH stromal cells by adenoviral-mediated overexpression of caspase-7. J Urol. 2000 Aug;164(2):518-25.
•   McConnell JD
  The pathophysiology of benign prostatic hyperplasia. J Androl. 1991 Nov-Dec;12(6):356-63. Review.
•   Radlmaier A, Eickenberg HU, Fletcher MS, Fourcade RO, Reis Santos JM, van Aubel OG, Bono AV
  Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group. Prostate. 1996 Oct;29(4):199-208.
•   Rhodes PR, Krogh RH, Bruskewitz RC
  Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology. 1999 Jun;53(6):1090-8. Review.
•   Wilt TJ, Ishani A, Rutks I, MacDonald R
  Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 2000 Dec;3(4A):459-72.
•   Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C
  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998 Nov 11;280(18):1604-9. Erratum in: JAMA 1999 Feb 10;281(6):515.
•   Zhu YS, Imperato-McGinley JL
  5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009 Feb;1155:43-56. doi: 10.1111/j.1749-6632.2009.04115.x. Review.

Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy.

Details for clinical trial NCT01275521